Pre-hypertension: another 'pseudodisease'?
Where this comes from
- Record sourced from PubMed, PMID 24229371.
- Also identified by DOI 10.1186/1741-7015-11-211 and PMC identifier PMC4313888.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hypertension is one of the most important and common cardiovascular risk factors. Defining the level at which blood pressure starts causing end-organ damage is challenging, and is not easily answered. The threshold of blood pressure defining hypertension has progressively been reduced over time, from systolic >160 mmHg to >150 mmHg, then to >140 mmHg; and now even blood pressures above 130 to 120 mmHg are labeled as 'pre-hypertension' by some expert committees. Are interest groups creating another 'pseudodisease' or is this trend scientifically justified? A recent meta-analysis published in BMC Medicine by Huang et al. clearly indicates that pre-hypertension (120 to 140/80 to 90 mmHg) is a significant marker of increased cardiovascular risk. This raises the question as to whether we now need to lower the threshold of 'hypertension' (as opposed to 'pre-hypertension') to >120/80 mmHg, redefining a significant proportion of currently healthy people as 'patients' with an established disease. These data need to be interpreted with some caution. It is controversial whether pre-hypertension is an independent risk factor or just a risk marker and even more controversial whether treatment of pre-hypertension will lower cardiovascular risk. Please see related research: http://www.biomedcentral.com/1741-7015/11/177.